semaglutide .5 SEMAGLUTIDE + CAGRILINTIDE 5 mg/5
Description
As we also previously reported in 2015 [90], ALT response was the best predictor of reduction in NAS or fibrosis regression in 52 Japanese patients with NASH undergoing repeated biopsies
Dose increases should always be guided by a healthcare provider and done gradually, typically every 24 weeks
Overall, research into semaglutide safety reports that it is well-tolerated by most study volunteers
Published April 14, 2025
